The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandem...
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease)....
Generar recomendaciones basadas en la mejor evidencia disponible acerca del manejo de personas con Leucemia Aguda 15 años y más....
Generar recomendaciones basadas en la mejor evidencia disponible acerca del manejo de personas de 15 años y más con Leucemia crónica. Personas de 15 años y más con Leucemia crónica que reciben atención en el nivel secundario y terciario de salud en el sector público y privado de salud....
This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life. A table of NHS England interim treatment regimens gives possible alter...
Dent, S;
Brezden-Masley, C;
Clarke, B;
Davis, MK;
Jassal, DS;
Johnson, C;
Lemieux, J;
Paterson, I;
Sebag, IA;
Simmons, C;
Sulpher, J;
Thain, K;
Thavendiranathan, P;
Wentzell, JR;
Wurtele, N;
Côté, MA;
Fine, NM;
Haddad, H;
Hayley, BD;
Hopkins, S;
Joy, AA;
Rayson, D;
Stadnick, E;
Straatman, L;
Virani, SA.
Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This ...
Antineoplásicos,
Biomarcadores,
Cardiotónicos,
Cardiotoxinas,
Troponina T,
Péptido Natriurético Encefálico,
Proteína C-Reactiva,
Antineoplásicos/efectos adversos,
Arritmias Cardíacas,
Cardiotoxicidad,
Trombosis Coronaria,
Diagnóstico Precoz,
Ecocardiografía Tridimensional,
Hipertensión/terapia,
Imagen por Resonancia Cinemagnética,
Isquemia Miocárdica,
Neoplasias/terapia,
Prevención Primaria,
Radioterapia,
Factores de Riesgo,
Disfunción Ventricular Izquierda,
Cardiotoxicidad/diagnóstico,
Cardiotoxinas/efectos adversos,
Radioterapia/efectos adversos
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagno...
La Esclerosis Múltiple (EM), corresponde a una enfermedad desmielinizante del Sistema Nervioso
Central (SNC), que se manifiesta con variada sintomatología deficitaria según el territorio
anatómico afectado. La EM presenta agregación familiar de base genética (antígenos de histocompatibilidad entre...
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who a...
Zinzani, Pier Luigi;
Marchetti, Monia;
Billio, Atto;
Barosi, Giovanni;
Carella, Angelo Michele;
Lazzarino, Mario;
Martelli, Maurizio;
Rambaldi, Alessandro;
Rigacci, Luigi;
Tarella, Corrado;
Vitolo, Umberto;
Tura, Sante.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
Anticuerpos Monoclonales,
Anticuerpos,
Anticuerpos Monoclonales de Origen Murino/uso terapéutico,
Antineoplásicos,
Esquema de Medicación,
Trasplante de Células Madre Hematopoyéticas,
Linfoma Folicular/patología,
Linfoma/terapia,
Estadificación de Neoplasias,
Rituximab,
Factores de Tiempo
